Should we use COMM (Current Opioid Misuse Measure) to screen for opioid abuse in patients with cancer pain? Journal Article
| Authors: | Moryl, N.; Mendoza, T. R.; Horn, S. D.; Eustaquio, J. C.; Cleeland, C. S.; Inturrisi, C. |
| Article Title: | Should we use COMM (Current Opioid Misuse Measure) to screen for opioid abuse in patients with cancer pain? |
| Abstract: | BACKGROUND: Growing concerns about opioid use disorder (OUD) and the resulting decrease in opioid availability for patients with cancer pain highlight the need for reliable screening tools to identify the subset of patients at increased risk for aberrant opioid use. Our study examines the utility of Current Opioid Misuse Measure (COMM) recommended by the NCCN Clinical Practice Guidelines in Oncology for Adult Cancer Pain. PATIENTS AND METHODS: We analyzed prospectively collected patient-reported outcomes of 444 consecutive patients with cancer seen in pain clinics of a cancer center at 2 time points within 100 days. The relationship of COMM to other OUD screening tools, pain, opioid doses, patient demographics, and mortality was examined using univariate and multivariable logistic regression. We also examined individual items of COMM for face validity. RESULTS: Among 444 patients who completed pain surveys at 2 time points, 157 (35.4%) did not complete COMM surveys. Using a COMM cutoff of ≥13, a total of 84 patients (29.3%; 84/287) scored positive for aberrant drug use. As patients remained on opioids for 49 to 100 days, the likelihood of improving COMM score (turning from positive to negative) was 6.1 times greater than the reverse. The number of patients with COMM ≥13 was 3.8 times higher than the number of patients with CPT diagnostic codes for OUD, 5.3 times higher than those with a positive urine drug screening, and 21 times higher than those with a positive CAGE (Cut Down, Annoyed, Guilty, Eye-Opener Questionnaire) score. COMM ≥13 was not associated with pain relief response (worst pain intensity score ≥2 points on the Brief Pain Inventory), opioid doses, gender, or age. Contrary to the intended use of COMM to identify aberrant opioid use, COMM ≥13 predicted mortality: patients with COMM ≥13 were 1.9 times more likely to die within 12 months. CONCLUSIONS: Our study found that using COMM in a cancer population may significantly overestimate the risk of opioid misuse. Using COMM without modifications can create an additional barrier to cancer pain management, such as limiting appropriate opioid use. |
| Keywords: | pain; opioids; addiction; cancer; comm |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 21 |
| Issue: | 11 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2023-11-01 |
| Start Page: | 1132 |
| End Page: | 1140 |
| Language: | English |
| DOI: | 10.6004/jnccn.2023.7054 |
| PUBMED: | 37935105 |
| PROVIDER: | scopus |
| PMCID: | PMC11110681 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Natalie Moryl -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work